Palisade Capital Management LLC NJ maintained its position in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 30,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. Palisade Capital Management LLC NJ’s holdings in Sucampo Pharmaceuticals were worth $315,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in SCMP. Capital Fund Management S.A. acquired a new position in Sucampo Pharmaceuticals during the first quarter valued at approximately $418,000. Algert Global LLC increased its position in Sucampo Pharmaceuticals by 18.5% in the first quarter. Algert Global LLC now owns 205,529 shares of the biopharmaceutical company’s stock valued at $2,261,000 after buying an additional 32,072 shares during the period. LSV Asset Management increased its position in Sucampo Pharmaceuticals by 11.4% in the first quarter. LSV Asset Management now owns 2,346,418 shares of the biopharmaceutical company’s stock valued at $25,810,000 after buying an additional 239,200 shares during the period. Eqis Capital Management Inc. increased its position in Sucampo Pharmaceuticals by 170.6% in the first quarter. Eqis Capital Management Inc. now owns 51,795 shares of the biopharmaceutical company’s stock valued at $570,000 after buying an additional 32,655 shares during the period. Finally, Great West Life Assurance Co. Can increased its position in Sucampo Pharmaceuticals by 900.8% in the first quarter. Great West Life Assurance Co. Can now owns 35,778 shares of the biopharmaceutical company’s stock valued at $392,000 after buying an additional 32,203 shares during the period. Institutional investors and hedge funds own 58.20% of the company’s stock.

Shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) opened at 10.50 on Thursday. The company’s 50-day moving average is $10.72 and its 200 day moving average is $10.69. Sucampo Pharmaceuticals, Inc. has a 52-week low of $9.30 and a 52-week high of $17.55. The company’s market cap is $485.04 million.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.06. The business had revenue of $59.90 million during the quarter, compared to analyst estimates of $56.44 million. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The company’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.24 EPS. On average, analysts anticipate that Sucampo Pharmaceuticals, Inc. will post $1.02 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Sucampo Pharmaceuticals, Inc. (SCMP) Stake Maintained by Palisade Capital Management LLC NJ” was published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/08/10/sucampo-pharmaceuticals-inc-scmp-stake-maintained-by-palisade-capital-management-llc-nj.html.

Several research firms recently commented on SCMP. Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 4th. ValuEngine upgraded shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Maxim Group restated a “buy” rating and issued a $23.00 price target (up from $21.00) on shares of Sucampo Pharmaceuticals in a research note on Tuesday. BidaskClub downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 5th. Finally, Roth Capital set a $30.00 price target on shares of Sucampo Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $17.63.

In related news, insider Jones W. Bryan bought 4,700 shares of Sucampo Pharmaceuticals stock in a transaction on Friday, August 4th. The stock was acquired at an average price of $10.60 per share, with a total value of $49,820.00. Following the acquisition, the insider now directly owns 4,700 shares of the company’s stock, valued at $49,820. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.13% of the stock is owned by insiders.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Want to see what other hedge funds are holding SCMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).

Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.